265 related articles for article (PubMed ID: 28379902)
1. Cangrelor: A New Route for P2Y12 Inhibition.
Sible AM; Nawarskas JJ
Cardiol Rev; 2017; 25(3):133-139. PubMed ID: 28379902
[TBL] [Abstract][Full Text] [Related]
2. Current status of data on cangrelor.
Qamar A; Bhatt DL
Pharmacol Ther; 2016 Mar; 159():102-9. PubMed ID: 26802900
[TBL] [Abstract][Full Text] [Related]
3. Cangrelor: a novel intravenous antiplatelet agent with a questionable future.
Waite LH; Phan YL; Spinler SA
Pharmacotherapy; 2014 Oct; 34(10):1061-76. PubMed ID: 25123696
[TBL] [Abstract][Full Text] [Related]
4. Meta-Analysis of the Role of Cangrelor for Patients Undergoing Percutaneous Coronary Intervention.
Majmundar M; Kansara T; Jain A; Shah P; Mithawala P; Desai R; Shah P; Doshi R
Am J Cardiol; 2019 Apr; 123(7):1069-1075. PubMed ID: 30654930
[TBL] [Abstract][Full Text] [Related]
5. Cangrelor - Expanding therapeutic options in patients with acute coronary syndrome.
Kubica J; Adamski P; Dobrzycki S; Gajda R; Gąsior M; Gierlotka M; Jaguszewski M; Legutko J; Lesiak M; Navarese EP; Niezgoda P; Ostrowska M; Pawłowski T; Tycińska A; Umińska JM; Witkowski A; Gil R
Cardiol J; 2024; 31(1):133-146. PubMed ID: 37964649
[TBL] [Abstract][Full Text] [Related]
6. Periprocedural platelet inhibition with cangrelor in P2Y
Droppa M; Spahn P; Takhgiriev K; Müller KAL; Alboji A; Straub A; Rath D; Jeong YH; Gawaz M; Geisler T
Int J Cardiol; 2016 Nov; 223():848-851. PubMed ID: 27580219
[TBL] [Abstract][Full Text] [Related]
7. Cangrelor: A Review in Percutaneous Coronary Intervention.
Keating GM
Drugs; 2015 Aug; 75(12):1425-34. PubMed ID: 26201463
[TBL] [Abstract][Full Text] [Related]
8. Cangrelor: Pharmacology, Clinical Data, and Role in Percutaneous Coronary Intervention.
Price MJ
Interv Cardiol Clin; 2017 Jan; 6(1):39-47. PubMed ID: 27886821
[TBL] [Abstract][Full Text] [Related]
9. What is the Role of Cangrelor in Patients Undergoing PCI?
Droppa M; Geisler T
Curr Vasc Pharmacol; 2018; 16(5):484-489. PubMed ID: 29345586
[TBL] [Abstract][Full Text] [Related]
10. Practical considerations for cangrelor use in patients with acute coronary syndromes.
Leonardi S; Bhatt DL
Eur Heart J Acute Cardiovasc Care; 2019 Feb; 8(1):39-44. PubMed ID: 28574274
[TBL] [Abstract][Full Text] [Related]
11. Cangrelor: a review on pharmacology and clinical trial development.
Franchi F; Rollini F; Muñiz-Lozano A; Cho JR; Angiolillo DJ
Expert Rev Cardiovasc Ther; 2013 Oct; 11(10):1279-91. PubMed ID: 24138516
[TBL] [Abstract][Full Text] [Related]
12. Cangrelor for treatment during percutaneous coronary intervention.
Oestreich JH; Dobesh PP
Future Cardiol; 2014 Mar; 10(2):201-13. PubMed ID: 24762247
[TBL] [Abstract][Full Text] [Related]
13. Cangrelor in Percutaneous Coronary Intervention: Current Status and Perspectives.
Alexopoulos D; Pappas C; Sfantou D; Lekakis J
J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):13-22. PubMed ID: 29228817
[TBL] [Abstract][Full Text] [Related]
14. Cangrelor for the treatment of arterial thrombosis: pharmacokinetics/pharmacodynamics and clinical data.
Tamborini Permunian E; Riva N; Guasti L; Squizzato A
Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):625-37. PubMed ID: 25728292
[TBL] [Abstract][Full Text] [Related]
15. Impact of Intravenous P2Y12-Receptor Inhibition with Cangrelor in Patients Presenting with Acute Coronary Syndrome and Cardiogenic Shock - a Case Series.
Droppa M; Borst O; Rath D; Müller K; Gawaz M; Bhatt DL; Geisler T
Cell Physiol Biochem; 2017; 42(4):1336-1341. PubMed ID: 28700987
[TBL] [Abstract][Full Text] [Related]
16. Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial.
Leonardi S; Mahaffey KW; White HD; Gibson CM; Stone GW; Steg GW; Hamm CW; Price MJ; Todd M; Dietrich M; Gallup D; Liu T; Skerjanec S; Harrington RA; Bhatt DL
Am Heart J; 2012 May; 163(5):768-776.e2. PubMed ID: 22607853
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials.
Angiolillo DJ; Schneider DJ; Bhatt DL; French WJ; Price MJ; Saucedo JF; Shaburishvili T; Huber K; Prats J; Liu T; Harrington RA; Becker RC
J Thromb Thrombolysis; 2012 Jul; 34(1):44-55. PubMed ID: 22569899
[TBL] [Abstract][Full Text] [Related]
18. Optimizing the Use of Cangrelor in the Real World.
Qamar A; Bhatt DL
Am J Cardiovasc Drugs; 2017 Feb; 17(1):5-16. PubMed ID: 27677505
[TBL] [Abstract][Full Text] [Related]
19. Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX.
Cavender MA; Harrington RA; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Lopes RD; Leonardi S; Deliargyris EN; Prats J; Mahaffey KW; White HD; Bhatt DL;
Circ Cardiovasc Interv; 2022 Jan; 15(1):e010390. PubMed ID: 34915723
[TBL] [Abstract][Full Text] [Related]
20. A Safety Evaluation of Cangrelor in Patients Undergoing PCI.
Franchi F; Rollini F; Park Y; Angiolillo DJ
Expert Opin Drug Saf; 2016; 15(2):275-85. PubMed ID: 26680584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
